Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLYM
stocks logo

CLYM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast CLYM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLYM is 9.25 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CLYM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLYM is 9.25 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.730
sliders
Low
8.00
Averages
9.25
High
10.00
Current: 1.730
sliders
Low
8.00
Averages
9.25
High
10.00
William Blair
Matt Phipps
Outperform
initiated
2025-10-16
Reason
William Blair
Matt Phipps
Price Target
2025-10-16
initiated
Outperform
Reason
William Blair analyst Matt Phipps initiated coverage of Climb Bio with an Outperform rating and no price target. The firm cites the potential of the company's CD19 antibody, budoprutug, which is being developed across a range of autoimmune indications, for the rating. The simplicity of a monoclonal antibody will be attractive for community physicians who treat most autoimmune patients, the analyst tells investors in a research note.
BTIG
Buy
maintain
$7 -> $8
2025-09-30
Reason
BTIG
Price Target
$7 -> $8
2025-09-30
maintain
Buy
Reason
BTIG raised the firm's price target on Climb Bio to $8 from $7 and keeps a Buy rating on the shares. With a positive dose-response seen with sibeprenlimab in IgAN, the firm believes that CLYM116 is well-positioned to drive even greater efficacy at two to three-times the half life compared to sibeprenlimab in NHPs - nonhuman primate, the analyst tells investors in a research note. The long half life also refuted any speculation that target-mediated drug disposition could impair CLYM116's PK, the firm added.
Baird
Outperform
initiated
$9
2025-08-15
Reason
Baird
Price Target
$9
2025-08-15
initiated
Outperform
Reason
As previously reported, Baird initiated coverage of Climb Bio with an Outperform rating and $9 price target. The firm believes Climb's lead drug budoprutug has potential across a wide range of immune-mediated diseases, building on validation from Uplizna, the analyst tells investors. Early clinical data for budoprutug in primary membranous nephropathy have shown positive efficacy and safety, notes the analyst, who adds that Climb is currently pursuing early-to-mid-stage studies in pMN as well as immune thrombocytopenia and systemic lupus erythematosus.
Baird
Colleen Kusy
Outperform
initiated
$9
2025-08-14
Reason
Baird
Colleen Kusy
Price Target
$9
2025-08-14
initiated
Outperform
Reason
Baird analyst Colleen Kusy initiated coverage of Climb Bio with an Outperform rating and $9 price target.
Oppenheimer
Oppenheimer
Outperform
initiated
$10
2025-06-06
Reason
Oppenheimer
Oppenheimer
Price Target
$10
2025-06-06
initiated
Outperform
Reason
BTIG
analyst
initiated
$7
2025-05-22
Reason
BTIG
analyst
Price Target
$7
2025-05-22
initiated
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Climb Bio Inc (CLYM.O) is -2.16, compared to its 5-year average forward P/E of -3.39. For a more detailed relative valuation and DCF analysis to assess Climb Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.39
Current PE
-2.16
Overvalued PE
-1.57
Undervalued PE
-5.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1599.17% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1599.17% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CLYM News & Events

Events Timeline

(ET)
2025-11-25
07:11:52
Climb Bio announces inducement grant in accordance with Nasdaq listing regulations
select
2025-11-06 (ET)
2025-11-06
07:31:48
Climb Bio Announces Q3 Earnings Per Share of 19 Cents Compared to 13 Cents Last Year
select
2025-10-21 (ET)
2025-10-21
07:05:48
Climb Bio Names Adam Villa as Senior Vice President of Technical Operations
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
10-21Newsfilter
Climb Bio Appoints Adam Villa as Senior Vice President of Technical Operations and Ashley Jones as Senior Vice President of People and Workforce Strategy

  • Leadership Appointments: Climb Bio, Inc. has appointed Adam Villa as Senior Vice President of Technical Operations and Ashley Jones as Senior Vice President of People & Workforce Strategy to enhance its leadership team during a critical growth phase.

  • Experience of New Leaders: Adam Villa brings over 20 years of biopharmaceutical experience, while Ashley Jones has nearly two decades in human resources within the biotechnology sector, both expected to contribute significantly to Climb Bio's clinical development and operational efficiency.

  • Inducement Equity Awards: As part of their employment agreements, Climb Bio granted inducement equity awards consisting of stock options for a total of 360,000 shares, with an exercise price of $2.32 per share, vesting over four years.

  • Company Overview: Climb Bio is focused on developing therapeutics for immune-mediated diseases, with key programs including budoprutug and CLYM116, aimed at treating various B-cell mediated diseases and IgA nephropathy, respectively.

[object Object]
Preview
9.0
10-17Benzinga
Climb Bio's Lead Drug Candidate Offers Significant Long-Term Potential for Small-Cap Biotech

  • Climb Bio Coverage Initiation: William Blair has initiated coverage of Climb Bio (NASDAQ: CLYM), highlighting the potential of its drug budoprutug for autoimmune conditions, with ongoing trials for immune thrombocytopenia, systemic lupus erythematosus, and an upcoming trial for primary membranous nephropathy.

  • Market Potential and Financial Outlook: Analyst estimates suggest a combined peak sales potential of $1.9 billion by 2040 for the three indications, with a risk-adjusted net present value of $812 million for Climb Bio, supporting an Outperform rating. The company also has plans for further development of CLYM116 for IgA nephropathy.

[object Object]
Preview
4.0
10-16Benzinga
Celestica Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations

  • Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing ratings and price targets for their stocks.

  • Climb Bio Inc: William Blair analyst Matt Phipps gave Climb Bio Inc (CLYM) an Outperform rating with shares closing at $1.94.

  • Rocket Lab Corp: Baird analyst Peter Arment rated Rocket Lab Corp (RKLB) as Outperform with a price target of $83, while shares closed at $69.27.

  • Vera Therapeutics Inc and Others: B of A Securities and Chardan Capital also initiated coverage on Vera Therapeutics Inc (VERA) and Opus Genetics Inc (IRD) with Buy ratings and respective price targets of $48 and $9.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Climb Bio Inc (CLYM) stock price today?

The current price of CLYM is 1.73 USD — it has decreased -0.57 % in the last trading day.

arrow icon

What is Climb Bio Inc (CLYM)'s business?

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

arrow icon

What is the price predicton of CLYM Stock?

Wall Street analysts forecast CLYM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLYM is 9.25 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Climb Bio Inc (CLYM)'s revenue for the last quarter?

Climb Bio Inc revenue for the last quarter amounts to -14.89M USD, increased 26.93 % YoY.

arrow icon

What is Climb Bio Inc (CLYM)'s earnings per share (EPS) for the last quarter?

Climb Bio Inc. EPS for the last quarter amounts to -12248000.00 USD, increased 62.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Climb Bio Inc (CLYM)'s fundamentals?

The market is revising No Change the revenue expectations for Climb Bio, Inc. (CLYM) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -27.62%.
arrow icon

How many employees does Climb Bio Inc (CLYM). have?

Climb Bio Inc (CLYM) has 17 emplpoyees as of December 05 2025.

arrow icon

What is Climb Bio Inc (CLYM) market cap?

Today CLYM has the market capitalization of 117.96M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free